Skip Navigation

Human Molecular Genetics 2006 15(Review Issue 1):R89-R93; doi:10.1093/hmg/ddl087
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Marsh, S.
Right arrow Articles by McLeod, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, S.
Right arrow Articles by McLeod, H. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Pharmacogenomics: from bedside to clinical practice

Sharon Marsh and Howard L. McLeod*

Division of Oncology, Washington University School of Medicine, St Louis, MO, USA

* To whom correspondence should be addressed at: Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA. Tel: +1 3147472060; Fax: +1 3143623764; Email: hmcleod{at}im.wustl.edu

Received February 1, 2006; Revised March 15, 2006; Accepted March 30, 2006

The field of pharmacogenomics has seen some exciting advances in the recent past. The Human Genome Project and International HapMap projects have uncovered a wealth of information for researchers. The discovery of clinically predictive genotypes (e.g. UGT1A1*28, TYMS TSER), haplotypes (e.g. VKORC1 Haplotype A) and somatic mutations (e.g. epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice. This review describes some of the recent advances in pharmacogenomics research.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo
Pharmacogenetics in cardiovascular antithrombotic therapy.
J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. A. Clayton, D. Baker, J. C. Lindon, J. R. Everett, and J. K. Nicholson
From the Cover: Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism
PNAS, August 25, 2009; 106(34): 14728 - 14733.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. G. McDonald, M. J. Rieder, M. Nakano, C. K. Hsia, and A. E. Rettie
CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
Mol. Pharmacol., June 1, 2009; 75(6): 1337 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
K. E. Varley and R. D. Mitra
Nested Patch PCR enables highly multiplexed mutation discovery in candidate genes
Genome Res., November 1, 2008; 18(11): 1844 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
A. E. Rettie and G. Tai
The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine
Mol. Interv., August 1, 2006; 6(4): 223 - 227.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.